

# Effect of Ingested Lipids on Drug Dissolution and Release with Concurrent Digestion: A Modeling Approach

Fulden Buyukozturk · Selena Di Maio · David E. Budil · Rebecca L. Carrier

Received: 11 March 2013 / Accepted: 20 October 2013 / Published online: 14 November 2013  
© Springer Science+Business Media New York 2013

## ABSTRACT

**Purpose** To mechanistically study and model the effect of lipids, either from food or self-emulsifying drug delivery systems (SEDDS), on drug transport in the intestinal lumen.

**Methods** Simultaneous lipid digestion, dissolution/release, and drug partitioning were experimentally studied and modeled for two dosing scenarios: solid drug with a food-associated lipid (soybean oil) and drug solubilized in a model SEDDS (soybean oil and Tween 80 at 1:1 ratio). Rate constants for digestion, permeability of emulsion droplets, and partition coefficients in micellar and oil phases were measured, and used to numerically solve the developed model.

**Results** Strong influence of lipid digestion on drug release from SEDDS and solid drug dissolution into food-associated lipid emulsion was observed and predicted by the developed model. Ninety minutes after introduction of SEDDS, there was 9% and 70% drug release in the absence and presence of digestion, respectively. However, overall drug dissolution in the presence of food-associated lipids occurred over a longer period than without digestion.

**Conclusion** A systems-based mechanistic model incorporating simultaneous dynamic processes occurring upon dosing of drug with lipids enabled prediction of aqueous drug concentration profile. This model, once incorporated with a pharmacokinetic model considering processes of drug absorption and drug lymphatic transport in the presence of lipids, could be highly useful for quantitative prediction of impact of lipids on bioavailability of drugs.

**KEY WORDS** biorelevant media · colloidal particles · computational modeling · EPR · food effect · mass transport · mechanistic modeling · self-emulsifying drug delivery systems

## ABBREVIATIONS

BS	bile salts
EPR	electron paramagnetic resonance
FA	fatty acids
GI	gastrointestinal
HPLC	high performance liquid chromatography
MG	monoglycerides
NaTDC	sodium taurodeoxycholate
PC	L- $\alpha$ -phosphatidylcholine
PL	phospholipids
SEDDS	self-emulsifying drug delivery systems
TB	TEMPOL benzoate

## INTRODUCTION

Ingested lipids, either originating from food or used as delivery agents, can have significant effects on dissolution, solubility, transport, and bioavailability of orally delivered compounds. The influence of ingested lipids on compound absorption originates from several mechanisms. Colloidal structures

**Electronic supplementary material** The online version of this article (doi:10.1007/s11095-013-1238-6) contains supplementary material, which is available to authorized users.

F. Buyukozturk · S. Di Maio · R. L. Carrier (✉)  
Department of Chemical Engineering, College of Engineering  
Northeastern University, 360 Huntington Avenue  
Boston, Massachusetts 02115, USA  
e-mail: rebecca@coe.neu.edu

F. Buyukozturk  
e-mail: fbuyukozturk@gmail.com

S. Di Maio  
e-mail: dimaio.s@husky.neu.edu

D. E. Budil  
Department of Chemistry and Chemical Biology, College of Science  
Northeastern University, 360 Huntington Avenue  
Boston, Massachusetts 02115, USA  
e-mail: d.budil@neu.edu

*Present Address:*  
F. Buyukozturk  
The MathWorks, Inc., 3 Apple Hill Drive  
Natick, MA 01760, USA

formed during lipid digestion, and compound trafficking between these structures and aqueous medium, impact solubility and dissolution. The presence of lipids in the gastrointestinal (GI) tract increases transit time, and can also facilitate the transport of lipophilic compounds via the lymphatic pathway, enabling avoidance of first-pass metabolism (1). However, these effects are typically documented as empirical, compound-specific observations and not predictable (2,3). Processes involved in enhancement of overall drug absorption by lipids: lipid digestion, drug dissolution/release, drug partitioning, and drug absorption, have frequently been studied in isolation and on disparate systems. Therefore, despite numerous studies about fat-rich food/drug interactions and lipid-based delivery systems, there is still an incomplete understanding—and thus a lack of general mechanistic modeling—of the influence of ingested lipids on *in vivo* oral bioavailability. The interconnected, dynamic processes that occur simultaneously during lipid digestion, and their dependence on dynamic system colloidal structure and composition, must be studied in a comprehensive, integrated fashion to enable quantitative prediction. Quantitative prediction of the impact of lipids on oral absorption would facilitate design of oral drug delivery systems and realization of the tremendous potential of lipids to impact bioavailability.

The goal of this study is to investigate quantitatively and model mathematically the influence of lipids originating either from i) food or ii) lipid based self-emulsifying drug delivery systems (SEDDS) on drug dissolution or drug release, respectively, in the presence of simultaneous digestion. Experimental studies were conducted in an *in vitro* simulated intestinal environment incorporating simulated intestinal fluids. The main differences between the cases of dosing food-associated lipids and SEDDS reflected in our experimental systems and models were: 1. the form of drug dosed (solid drug co-dosed with soybean oil as a model lipid, *vs.* drug dissolved in an oil/surfactant mixture as a model SEDDS formulation); 2. ratio of lipid to intestinal fluid volumes; 3. the simulated intestinal fluid composition (reflecting fed and fasted states, respectively). The extent of the lipid digestion was monitored experimentally by basic titration technique. Kinetics of drug dissolution/release and partitioning among colloidal phases (oil, micellar, aqueous) were analyzed by high performance liquid chromatography (HPLC) and electron paramagnetic resonance (EPR), respectively.

EPR (also called electron spin resonance, or ESR) is a non-invasive technique that makes it possible to detect and quantify paramagnetic molecules such as organic radicals. Because many systems of interest are not paramagnetic, a common approach is the spin labeling or spin probe technique, in which a stable radical such as a nitroxide is introduced into the system to act as a reporter on the local environment. This method has been widely employed in the study of condensed phases, membranes, and biopolymers


(4–6), although its application in drug delivery studies has been hitherto rather limited (7). In the present application, spin probes are used to monitor the microenvironment in different phases, e.g., colloidal particles such as emulsion droplets and micelles, compared to aqueous media. Since EPR spectra are highly sensitive to changes in local polarity and viscosity, the spin probes in different phases can be resolved and quantified so that the partitioning and translocation of probes between different phases can be monitored and quantified in real-time. In this study, the spin probe TEMPOL benzoate (TB) was selected as a model for poorly water-soluble moderately lipophilic drug with an octanol/water partition coefficient (logP) of 2.46 (7).

Based on these quantitative analyses, we developed systems-based models that predict the rate at which drug enters the aqueous intestinal environment, after dosing either in solid form with food-associated lipids, or incorporated into a SEDDS formulation. These models include mathematical expressions that describe key parallel kinetic processes occurring in the GI tract upon co-dosing of a compound with lipids. The processes considered include compound dissolution (if solid drug is dosed), compound release (if dosed in SEDDS), lipid digestion, and compound partitioning into colloidal phases (Fig. 1). In modeling both drug dissolution in the presence of food-associated lipids and drug release from SEDDS, the influence of colloids interacting with the drug on drug transport rates was explicitly taken into account. The ability of the models to predict the rate at which the drug enters the aqueous intestinal environment in the presence of the lipid digestion process was evaluated. Ultimately, the absorption process can be incorporated into these models to enable quantitative prediction of the impact of ingested lipids on oral compound absorption and bioavailability.

## MATERIALS AND METHODS

### Materials

Trizma® maleate, sodium chloride (NaCl), calcium chloride dihydrate  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ , sodium azide ( $\text{NaN}_3$ ), sodium hydroxide (NaOH), sodium taurodeoxycholate (NaTDC or BS, cat. # T0875), L-alpha-phosphatidylcholine from egg yolk (PC), Type XVI-E (cat. # P3556), soybean oil, Tween 80, porcine pancreas lipases (cat. # L3126), 4-bromobenzenboronic acid, and the model drug TB (cat # 371343) were purchased from Sigma-Aldrich Co., St. Louis, MO, USA. Polytetrafluoroethylene (PTFE) filters, nylon syringe filters as well as HPLC grade solvents utilized as mobile phases, methanol, water and trifluoroacetic acid (TFA), were purchased from Fisher Scientific, Pittsburgh, PA.



**Fig. 1** Schematic representation of two lipid systems studied: (a) solid drug dosed with food-associated lipid, (b) drug dosed in a lipid-based drug delivery system. Processes relevant to each system appear in blue text.  $C_{D,water}$ : free drug concentration,  $C_{D,aqueous}$ : free and micelle-associated drug concentration,  $C_{D,em}$ : drug concentration in food-associated oil and formulation emulsions,  $h$ : static layer around the dissolving drug particles.

### Preparation of the Biorelevant Media

Simulated intestinal fluid compositions used in this study were similar to ones proposed earlier (8,9), but modified slightly with respect to model bile component concentrations, salt concentrations, and pH considering physiological conditions for both fasted (10) and fed state systems (11) (Table I). The biorelevant medium simulating the intestinal fasted state contained maleate buffer that consisted of 100 mM Trizma® maleate, 65 mM NaCl, 5 mM or 10 mM (fasted or fed)  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ , and 3 mM  $\text{NaN}_3$  at pH 6.5. 5 mM NaTDC/1.25 mM PC and 12 mM NaTDC/4 mM PC were used in order to mimic fasted and fed state conditions, respectively. Model bile components were mixed with maleate buffer on a stirring plate at 37°C. In order to simulate SEDDS oral dosing in fasted state conditions, SEDDS formulation composed of soybean oil and Tween 80 at 1:1 weight ratio was added to fasted state simulated intestinal fluid at 1:100 volume ratio. To simulate the food-associated lipid intake, soybean oil was added to fed state simulated intestinal fluid at a final concentration of 50 mM in order to form a crude emulsion. Emulsification of soybean oil into fed state medium and formulation into fasted state medium was achieved by means of continuous magnetic stirring at 300 rpm and was verified by dynamic light scattering (DLS) (Brookhaven 90 Plus)

**Table I** Compositions of Two Separate Systems Studied: a) SEDDS in Fasted State, b) "Food Lipid" (Soybean Oil) in Fed State Biorelevant Media

	a) Lipid-based drug delivery system in fasted state		b) Food lipids in fed state	
Maleate buffer	pH 6.5		pH 6.5	
	Trizma® maleate	100 mM	Trizma® maleate	100 mM
	NaCl	65 mM	NaCl	65 mM
	$\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$	5 mM	$\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$	10 mM
	$\text{NaN}_3$	3 mM	$\text{NaN}_3$	3 mM
	NaOH	40 mM	NaOH	40 mM
Bile salt	NaTDC	5 mM	NaTDC	12 mM
Phospholipid	Lecithin	1.25 mM	Lecithin	4 mM
Ratio BS/PL	4:1		3:1	
Lipid substrate	SEDSS formulation: Soybean oil:Tween 80 1:1 (w/w), 1:100 formulation dilution in fasted state solution		Soybean oil	50 mM

measurements performed immediately upon sampling, before separation of phases might have occurred.

### Solubility Measurements

Studies pertaining to *in vitro* drug dissolution, drug release and lipid digestion were performed with a model compound, the spin probe TB, in order to enable use of EPR to validate model simulations (in case of SEDDS) and to calculate partition coefficients (in case of food-associated lipid). The equilibrium solubility of the model drug TB was measured by adding excess amount of compound dissolved into water (used as a control), maleate buffer at pH 6.5, fasted and fed state biorelevant media, SEDDS formulation, and soybean oil according to the shake-flask method. Samples were stirred at 37°C, 300 rpm for 72 h on a hot stirring plate, and sampled every 24 h (or until equilibrium solubility was attained). For determining aqueous solubility of TB in the presence of Tween 80 associated micelles (originating from SEDDS formulation), formulation was dispersed in fasted state biorelevant medium at 1:100 dilution together with excess TB and stirred at 37°C, 300 rpm for 72 h, and samples collected every 24 h were filtered through 0.1  $\mu\text{m}$  polytetrafluoroethylene (PTFE) syringe filters to remove emulsion droplets. The absence of emulsion droplets in the filtrate was validated by DLS measurements. Samples of aqueous solutions were centrifuged at  $1,700 \times g$  and 37°C for 30 min, while the oil and formulation samples were centrifuged at  $16,100 \times g$  for 30 min. The supernatant was filtered through 0.45  $\mu\text{m}$  nylon syringe filters, and properly diluted in isopropanol/methanol 2:1 (v/v) prior to measuring

drug concentration by means of HPLC. Experiments were conducted in triplicate for each dissolving medium and standard error was calculated.

### Drug Dissolution

In dissolution experiments, relevant to the case of dosing drug as a solid together with food-associated lipids (Fig. 1a), the solid model drug TB was added to a stirred beaker (0.003618 mmol/ml) containing the dissolving medium (maleate buffer at pH 6.5, or fed state biorelevant medium with and without soybean oil) at 37°C and 250 rpm. Experiments in fed state biorelevant medium with soybean oil were conducted in the presence of pancreatin extract, containing lipases, in order to assess the impact of the lipid digestion process on drug dissolution. Samples were withdrawn from the dissolution beaker at defined time intervals over a period of 3 h. Dissolution only samples were filtered through 0.45 µm nylon syringe filters to remove undissolved drug; simultaneous dissolution and digestion samples were centrifuged at  $1,700 \times g$  and 37°C for 10 min instead of filtered to remove undissolved drug and not oil emulsions (12). All samples were analyzed via HPLC in order to determine the drug concentration in solution. Experiments were conducted in triplicate for each dissolving medium and standard error was calculated.

### Drug Release

Drug release from SEDDS formulations (Fig. 1b) was tested in a stirred beaker at 37°C and 180 rpm in the absence and presence of pancreatin extract. In the absence of digestion, 400 µl of formulation including 50 mg/ml TB was added into 40 ml fasted state biorelevant media. Over time, 2 ml samples were taken from the beaker and filtered through 0.1 µm polytetrafluoroethylene (PTFE) syringe filters to separate aqueous solution containing micelles from formulation emulsion droplets. Filtered solution was analyzed using HPLC for TB content. Standard error was calculated using two independent measurements. In separate experiments in the presence of digestion, 200 µl formulation including 7 mg/ml TB was added into 200 ml fasted state solution. 1 ml samples were taken from the beaker, digestion process was terminated by the addition of enzyme inhibitor, 4-bromophenacyl bromide (4-BPB), and samples were directly analyzed using EPR as described in “[Electron Paramagnetic Resonance \(EPR\) Measurements](#)”.

### Quantification of TB from Solubility, Dissolution, and Release Experiments Using HPLC

The concentrations of the model drug TB in samples collected during solubility, dissolution, and release experiments were

determined using HPLC with a photodiode detector (Shimadzu, Japan), and a wavelength of 232 nm. The analytical column used was Agilent Zorbax RX-C18 4.6 × 75 mm, 3.5 µm. The column temperature was maintained at 40°C, and the flow rate was 1 mL/min. The mobile phase contained distilled water with 0.15% TFA: methanol (70:10 to 10:70 over 16 min).

### Digestion Kinetics

For *in vitro* digestion of soybean oil, soybean oil (50 mM) was added into the fed state biorelevant medium at 37°C, 250 rpm, and solution was equilibrated for 20 min prior to the addition of the model drug TB and the lipase enzyme. The lipid digestion and the dissolution processes were then commenced at the same time. *In vitro* lipolysis of SEDDS formulations (Fig. 1b) was performed by addition of 180 µl SEDDS formulation into 18 ml fasted state simulated intestinal fluid (1:100 dilution ratio), prepared as described in “[Preparation of the Biorelevant Media](#)”, at 37°C and 250 rpm.

In all *in vitro* lipolysis experiments, the enzymatic hydrolysis of lipids was initiated by adding 2 ml pancreatin extract into the simulated intestinal fluids containing the lipid substrates (soybean oil or SEDDS formulation) (13). Pancreatin extract was prepared fresh for every *in vitro* lipolysis experiment following the procedure described by Sek *et al.* (13). Briefly, 2 g of porcine pancreatin powder were dissolved in 10 ml of maleate buffer (composition in Table I) and magnetically stirred for 15 min at room temperature. The solution was centrifuged at  $1,600 \times g$  for 15 min at 5°C; the supernatant was collected and stored at 4°C until use. Measured enzyme activity of pancreatic lipase prepared in this manner from this supplier was similar to human pancreatic lipase activity *in vivo* (14). The change in pH was constantly monitored with a pH meter (Seven Multi pH meter, Mettler Toledo, Columbus, OH), and fatty acids (FA) reduced due to the lipolysis reaction were titrated manually with 0.2 mM NaOH using a digital titration unit (VWR international, Plainfield, NJ). FA production was then calculated by measuring the total volume of NaOH added to maintain the pH at 6.5 during lipolysis. Digestion rate was related to the droplet surface area available to the enzyme, as explained in “[Digestion](#)”. Digestion rate constants were estimated via non-linear regression fitting in MATLAB® using Eq. 4.

### Model Development

Kinetic expressions describing the rate of drug entering the aqueous environment after dosing either a drug-loaded SEDDS or a solid drug co-administered with food lipids were developed considering major kinetic processes that occur simultaneously *in vivo* (Fig. 1): formulation or lipid digestion,



solid drug dissolution, drug release from formulation (i.e. SEDDS) emulsion droplets or drug uptake into food lipid emulsion droplets, and drug partitioning into micelles. Formulation or food-associated lipid was assumed to enter directly to small intestine upon oral administration.

### Digestion

Digestion rate was expressed using a modification of equation recently proposed by Li *et al.* relating the rate of FA production to the droplet surface area available to the enzyme, assuming that the droplet size of oil-in-water emulsions decreases as digestion proceeds, and as FA, products of digestion of oil and surfactant, leave oil droplets (15). In many cases, only a fraction of the total digestible FA present initially in the oil droplets is released because the lipolysis reaction is inhibited by FA formation *in vitro* (16). In order to take this into account, we modified the expression proposed by Li *et al.* to include inhibition proportional to the concentration of FA:

$$\frac{dC_{FA,aq}}{dt} = k_{dig} \frac{A_{em}}{V_{aq}} - k_{inh} C_{FA,aq} \quad (1)$$

where  $C_{FA,aq}$  is the concentration of FA produced during the lipid digestion and released in the aqueous phase,  $k_{dig}$  is the digestion rate constant,  $A_{em}$  is the total oil droplet surface area per total solution volume,  $V_{aq}$  is the total solution volume (oil emulsions and aqueous phase), and  $k_{inh}$  is the inhibition rate constant.

It is assumed that during digestion, oil droplets will shrink in size over time due to enzymatic reaction and this change in particle diameter,  $D(t)$  can be related to the fraction of fatty acids released from the droplets due to digestion. Hence, time dependent total surface area of the emulsion droplets,  $A_{em}(t)$ , is

$$A_{em}(t) = N\pi \left( D_0 \sqrt{\frac{m_{FA,0} - C_{FA,aq} V_{aq}}{m_{FA,0}}} \right)^2 \quad (2)$$

where,  $N$  is the number of oil droplets present,  $m_{FA,em}$  is the moles of digestible FA remaining in the emulsion droplet,  $m_{FA,0}$  is the initial moles of digestible FA in the droplet, and  $D_0$  is the initial droplet diameter of emulsion droplets.

### Solid Drug Dissolution

The dissolution kinetics was expressed according to a static layer model that takes into account the contribution of colloidal particles to the drug transport rate, derived by Higuchi (17). Assuming the presence of a single species of free colloid (micelles), no net changes in colloid number, and

that solute/colloid interactions occur rapidly enough relative to other processes to be considered at equilibrium, the rate of drug dissolution in the aqueous phase (water and micelles) is:

$$\frac{dC_{D,aq}}{dt} = \frac{S_p}{V_{aq}h} \left[ D_s \left( C_{D,water}^{eq} - C_{D,water} \right) + D_m \left( C_{D,micelles}^{eq} - C_{D,micelles} \right) \right] \quad (3)$$

where  $C_{D,aq}$  is the drug concentration in the aqueous phase (mg/ml),  $S_p$  is the surface area of  $N$  dissolving drug particles ( $\text{cm}^2$ ),  $h$  is the stationary diffusion layer around a dissolving particle (cm),  $V_{aq}$  is the solution total volume (ml),  $D_s$  is the drug diffusion coefficient in water ( $\text{cm}^2/\text{s}$ ),  $C_{D,water}^{eq}$  is the drug solubility in water (mg/ml),  $C_{D,water}$  is the free drug concentration in the total solution volume (mg/ml),  $D_m$  is the micelle diffusion coefficient in water ( $\text{cm}^2/\text{s}$ ),  $C_{D,micelle}^{eq}$  is the drug solubility in micelles (mg/ml), and  $C_{D,micelles}$  is the drug concentration in micelles (mg/ml), where concentrations of drug in micelles are expressed as mass of drug in micelles per total volume of solution, at the concentration of micelles present in the solution. If the dissolving drug particles are assumed to be mono-dispersed and uniform spheres with an initial radius  $r_0$ , and the total number of particles  $N$  does not vary with time, then the time-dependent expression for  $S_p$  can be written as:

$$S_p = \frac{3M_0^{1/3}M_s^{2/3}}{\rho r_0} \quad (4)$$

where  $M_0$  is the initial mass of drug dosed (mg),  $M_s$  is the mass of undissolved drug (mg), and  $\rho$  is the drug density ( $\text{mg}/\text{cm}^3$ ) (18). Equilibrium solubility terms were determined experimentally by means of HPLC, as described in “Solubility Measurements”. The quantities  $C_{D,water}$  and  $C_{D,micelles}$  were calculated from the total measured drug in the aqueous phase (buffer and micelles) according to the partition coefficient  $P_{m/w}$  (see “Definition of Partition Coefficient,  $K$ ” for definition of partition coefficients). Diffusion coefficients for compounds and colloidal particles were calculated according to the Wilke-Chang and the Stokes-Einstein equations, respectively (“Estimation of the Diffusion Coefficients”).

Equation 3 was used to model solid drug dissolution data from experiments performed in biorelevant media without lipids or lipid digestion. In experiments performed in the presence of a lipid substrate, oil droplets (soybean oil) are detected by DLS to be bigger than micelles (200 nm *versus* 5 nm), and consequently to have a calculated diffusion coefficient of  $1.64 \times 10^{-12} \text{ m}^2/\text{s}$  (according to the Stoke-Einstein equation, “Estimation of the Diffusion Coefficients”) and an estimated diffusion time  $t$  through  $h$  ( $t = h^2/D$ ) of

~4 min, compared to ~6 s for micelles. Therefore, oil droplet contribution to the drug transport rate within the static diffusion layer  $h$  was neglected. However, some dissolved compound at each time  $t$  does transfer into the oil phase. Compound partitioning into oil droplets was considered using an interfacial barrier-limited model (19), rather than a diffusion-driven process as described by Eq. 3. The rate (mg/ml\*s) of drug partitioning into the oil phase is expressed as:

$$\frac{dC_{D,em}}{dt} = \frac{A_{em}P_{rel}}{V_{em}}(C_{D,aq} - C'_{D,aq}) \quad (5)$$

where  $A_{em}$  is the surface area of  $N$  oil droplets ( $\text{cm}^2$ ),  $P_{rel}$  is the permeability ( $\text{cm/s}$ ),  $V_{em}$  is the total oil volume dispersed in the aqueous solution,  $C_{D,aq}$  is the drug concentration (mg/ml) in the aqueous medium  $V_{aq}$  (buffer and micelles), and  $C'_{D,aq}$  is the hypothetical aqueous drug concentration (mg/ml) in equilibrium with the drug concentration inside oil droplets  $C_{D,em}$  (mg/ml). Calculation of  $C'_{D,aq}$  as a function of the drug partition coefficient between the aqueous phase and the oil phase,  $K_{aq/em}$ , is explained in “Definition of Partition Coefficient,  $K$ ”.  $P_{rel}$  was experimentally determined by means of EPR during drug partitioning experiments in the absence of lipolysis (“Electron Paramagnetic Resonance (EPR) Measurements”).

In experiments combining dissolution of the solid drug compound and *in vitro* lipolysis processes, specific parameters in the above expressions are expected to change, reflecting the dynamic nature of the digestion system.  $A_{em}$  is expected to decrease over time according to Eq. 2, taking into account lipolysis kinetics (15) (“Digestion”). Furthermore, as the lipase enzyme digests the lipids, micelles are expected to evolve into new colloidal structures due to the interaction with lipid digestion products FA and monoglycerides (MG) liberated in solution. The dynamic evolution of colloidal structures affects their solubilization power  $C_{D,micelle}^{eq}$  in Eq. 3 expressed as the quantity of dissolved drug associated with micelles per bulk volume. Therefore, the colloid solubilization power was affected by the extent of digestion and was no longer a constant during the dissolution process. The time-dependent colloid solubilization power,  $C_{D,micelle}^{eq}$ , was thus expressed as a function of the digestion kinetics as explained in detail in “Definition of Partition Coefficient,  $K$ ”.

Combining the two kinetic expressions (Eqs. 3 and 5) describing the drug dissolution rate in the aqueous phase  $C_{D,aq}$ , and the concurrent lipid digestion, the main equations utilized to describe FA and dissolved drug concentration profiles, respectively, are Eq. 1 and:

$$\begin{aligned} \frac{dC_{D,aq}}{dt} = & \frac{S_p}{V_{aq}h} \left[ D_s \left( C_{D,water}^{eq} - C_{D,water} \right) + D_m \left( C_{D,micelles}^{eq} - C_{D,micelles} \right) \right] \\ & - \frac{A_{em}P_{rel}}{V_{em}} \left( C_{D,aq} - C'_{D,aq} \right) \end{aligned} \quad (6)$$

### Drug Release from SEDDS Formulation Emulsions

In the case of dosing a lipid-based drug delivery system (SEDDS), drug is delivered already solubilized in emulsion droplets, and thus a process that occurs in parallel to formulation digestion is the drug release from inside of oil droplets to the surrounding aqueous media. Drug release was described using a kinetic expression developed by Higuchi *et al.* (19) considering interfacial resistance at the oil–water interface as a limiting barrier to compound transport, which is the same as Eq. 5 used in “Solid Drug Dissolution”.

However, along with the concentration gradient driven transport of compounds from inside the oil droplets into the aqueous media, there will be a compound transport from oil droplets into the aqueous media due to detachment of oil digestion products from the surface of the droplets. In order to account for compound transport due to digestion, drug release expression was modified to give:

$$\frac{dC_{D,aq}}{dt} = -\frac{A_{em}P_{rel}}{V_{aq}}(C_{D,aq} - C'_{D,aq}) + k_{dig} \frac{A_{em}}{V_{aq}} \frac{1}{n} V_{molar,em} C_{D,em} \quad (7)$$

where  $n$  is the moles of FA produced per mole of formulation and  $V_{molar,em}$  is averaged molar volume of the formulation content.  $C'_{D,aq}$  was expressed as a function of  $C_{D,em}$  and a partition coefficient,  $K$ , as described below in “Definition of Partition Coefficient,  $K$ ”.  $C_{D,em}$  was calculated using mass balance.  $P_{rel}$  was calculated experimentally by means of drug release experiments in the absence of digestive enzyme,  $k_{dig}$  was measured experimentally by *in vitro* lipolysis analysis, and time dependent change in emulsion droplet surface area,  $A_{em}$ , was calculated for each time point using Eq. 2. Combining the two kinetic processes, digestion and release, the main equations used to describe aqueous FA and drug concentration profiles, respectively, are Eqs. 2 and 7.

### Definition of Partition Coefficient, $K$

$C'_{D,aq}$ , hypothetical aqueous concentration of the solute in equilibrium with compound concentration inside emulsion droplet, is defined by the formulation/oil–aqueous phase partition coefficient,  $K_{em/aq}$ , as:

$$K_{em/aq} = \frac{C_{D,em}^{eq}}{C_{D,aq}^{eq}} = \frac{C_{D,em}^{eq}}{C_{D,water}^{eq} K_{m/w} + C_{D,water}^{eq}} = \frac{C_{D,em}}{C'_{D,aq}} \quad (8)$$

where  $C_{D,em}^{eq}$  is the equilibrium solubility concentration of drug in oil emulsions based on emulsion volume,  $C_{D,aq}^{eq}$  is the equilibrium solubility concentration of drug in the aqueous phase based on the aqueous volume and  $K_{m/w}$  is micelle-water partition coefficient. Using Eq. 8, hypothetical drug concentration in aqueous phase ( $C'_{D,aq}$ ) can be calculated using values for  $K_{em/aq}$  and time dependent drug concentration inside emulsion droplets,  $C_{D,em}$ . During digestion, we assume that digestion products that leave oil droplets incorporate into micelles, and as a result, the solubilization capacity of aqueous phase,  $C_{D,aq}^{eq}$ , increases and therefore  $K_{em/aq}$  changes over time.

In order to calculate  $K_{em/aq}$  over time during digestion, a constant term, molar solubilization capacity of micelles,  $\chi$ , was introduced and water partition coefficient,  $K_{m/w}$ , was expressed as a function of amount of total surfactant that is incorporated into micelles (both endogenous and due to digestion),  $C_{surf}$ . Molar solubilization capacity of micelles,  $\chi$  is defined as (20):

$$\chi = \frac{C_{D,aq}^{eq} - C_{D,water}^{eq}}{C_{surf} - cmc} \quad (9)$$

where  $cmc$  is the critical micelle concentration and  $C_{surf}$  is the time dependent molar concentration of total surfactant (BS, PL, FA) at a given point in time. We assume that as digestion products partition into BS/PL micelles, micelle composition changes, while the number of micelles remains constant. Total surfactant concentration,  $C_{surf}$ , is expressed as:

$$C_{surf} = C_{BS} + C_{PL} + C_{Tween80} + C_{FA,aq} \quad (10)$$

where  $C_{BS}$  is BS concentration,  $C_{PL}$  is PL concentration, and  $C_{Tween80}$  is amount of formulation component Tween 80 in aqueous phase (as opposed to formulation emulsions). Using Eq. 11, micelle water partition coefficient,  $K_{m/w}$ , is expressed as a function of the amount of surfactant that is associated with micelles and  $\chi$ :

$$K_{m/w} = \frac{C_{D,micelle}^{eq}}{C_{D,water}^{eq}} = \frac{C_{D,aq}^{eq} - C_{D,water}^{eq}}{C_{D,water}^{eq}} = \frac{\chi(C_{surf} - cmc)}{C_{D,water}^{eq}} \quad (11)$$

where  $C_{D,micelle}^{eq}$  is the equilibrium solubility of drug in micelles based on the total aqueous volume and  $C_{D,water}^{eq}$  is the equilibrium solubility of the drug in the water phase. Micelle molar solubilization capacity,  $\chi$ , is a constant and can be experimentally determined, as well as the drug solubility at equilibrium,  $C_{D,water}^{eq}$ . Critical micelle concentration,  $cmc$ , is also a constant (21).

## Estimation of the Diffusion Coefficients

Drug diffusion coefficient of TB,  $D_D$ , was estimated using Wilke-Chang equation (22):

$$D_{AB} = 7.4 \times 10^{-8} \frac{\sqrt{\psi_B MW_B} T}{\eta_B \bar{V}_A^{0.6}} \quad (12)$$

where  $D_{AB}$  is the diffusivity of compound A in solvent B ( $\text{cm}^2/\text{s}$ ),  $\psi_B$  is the constant that accounts for solvent/solvent interactions (2.6 for water),  $T$  is temperature (K),  $\eta_B$  is the viscosity of solvent B (cP),  $MW_B$  is molecular weight of solvent B (g/mol), and  $\bar{V}_A$  is the molar volume of compound A. According to Eq. 12, the diffusion coefficient of TB,  $D_D$ , was  $8.3743 \times 10^{-6} \text{ cm}^2/\text{s}$ .

Diffusion coefficient of mixed micelles,  $D_m$ , was estimated using the Stokes-Einstein equation (23):

$$D_{AB} = \frac{kT}{6\pi\eta_B r_A} \quad (13)$$

where  $D_{AB}$  is the diffusivity of compound A in solvent B ( $\text{cm}^2/\text{s}$ ),  $k$  is the Boltzman constant ( $1.3806 \times 10^{-23} \text{ m}^2 \text{ kg s}^{-2} \text{ K}^{-1}$ ),  $T$  is temperature (K),  $\eta_B$  is the viscosity of solvent B (Pa\*s), and  $r_A$  is the hydrodynamic radius of the particle (m). According to Eq. 13, the diffusion coefficient of micelles,  $D_m$ , was  $6.5578 \times 10^{-11} \text{ cm}^2/\text{s}$ . In both diffusivity estimations, the viscosity of the solvent  $\eta_B$  was assumed to be equal to the water value at  $37^\circ\text{C}$  ( $0.00069244 \text{ Pa*s}$ , or  $0.69244 \text{ cP}$ ) and the temperature was fixed at the physiological value of  $310^\circ\text{K}$ .

## Numerical Solutions of the Model Differential Equations

Differential equations pertaining to the developed mathematical model were solved using a built-in ordinary differential equation solver, ode45, in MATLAB® by means of the Runge-Kutta numerical solution technique. Concentrations of the drug in the aqueous phase, of the drug inside formulation emulsions, and of the FA produced via digestion in the aqueous phase were computed over time.

## Electron Paramagnetic Resonance (EPR) Measurements

In an effort to measure TB transport from aqueous solution into food lipids, EPR measurements of samples containing soybean oil in pre-lipolysis conditions (i.e. without lipase) were performed. Based on quantitative information obtained by EPR measurements for drug concentration in each phase (oil, micelle, aqueous), partition coefficients used in simulations of the impact of ingested food lipids (“Definition

of Partition Coefficient,  $K^*$ ) were estimated. In addition, the applicability of the interfacial barrier-limited model to describe compound partitioning into oil droplets was validated. TB was dissolved in the biorelevant medium before the addition of 50 mM soybean oil, after which samples were collected at different time points (up to 3 h) and analyzed by EPR in order to follow drug partitioning between phases (aqueous and oil).

In order to measure drug release from SEDDS emulsion droplets into aqueous solution during digestion, EPR measurements were performed on samples collected at different time points (0, 5, 20, 50 min) during *in vitro* digestion experiments as explained in “Digestion Kinetics”. Quantitative information obtained by EPR measurements for drug concentration in each phase during digestion (emulsion, micelle, and aqueous) was used as a means of model simulation validation for drug release from SEDDS during digestion.

Samples collected during experiments were analyzed immediately by EPR spectroscopy (9.1–9.9 GHz, X-Band; Bruker EMX) in an effort to perform real time quantitative non-invasive tracking of drug between emulsion droplets, aqueous and colloidal phases (micelles and vesicles). The parameters used during EPR measurements were as follows: microwave bridge frequency: 9.38 GHz, modulation frequency: 100 kHz; microwave power: 1 mW; sweep width: 70 G, sweep time: 83.89 s; time constant: 327.68 ms; modulation amplitude: 1 G. Quantitative determination of the ratio of the spin probe in different environments over time was performed via multi-component fitting analysis of spectra using the Multicomponent EPR LabVIEW module of Altenbach (24) to perform Simplex fitting of the spectrum.

## RESULTS

Lipid digestion kinetics and drug transport kinetics for both systems (Fig. 1a and b) were studied experimentally. Simulations describing drug transport in presence of lipid digestion for both systems were run and validated using experimental data.

### Ingested Food Lipids

#### Calculation of Digestion Kinetic Constant

The digestion kinetic constants for lipolysis of 50 mM soybean oil in the fed state biorelevant medium were determined according to Eq. 2 as  $k_{dig} = 3.6 \pm 0.2 \times 10^{-9}$  mmol/cm<sup>2</sup>s and  $k_{inh} = 4.3 \pm 0.3 \times 10^{-4}$  1/s, based on experimental measurement of digestion kinetics (Fig. 2). The excellent model fit (Eq. 2) supports the theoretical description of digestion rate as proportional to emulsion droplet surface area

and inhibited at a level proportional to the concentration of FA produced.

#### Drug Dissolution Without Lipids

Dissolution kinetics and solubility values of the model drug TB were measured in maleate buffer, and in fed state biorelevant medium by means of HPLC (Fig. 3). Significant (8 fold) improvement in solubility was observed for TB in fed state biorelevant medium relative to maleate buffer due to the presence of mixed micelle-forming species, NaTDC and lecithin (Table II). Improvement in dissolution kinetics was also evident from maleate buffer to fed state biorelevant medium, as shown by the steeper slope of the initial part of the dissolution curve in medium containing micelles.

#### Drug Dissolution in the Presence of Lipids


In dissolution experiments coupled with *in vitro* lipid digestion, dissolution kinetics of the model drug TB was determined as the digestion of 50 mM soybean oil—representing the lipid intake—proceeded (Fig. 2). The fed state biorelevant medium enriched by ingested lipids showed an approximately 4-fold further enhancement in solubilization power after 3 h of dissolution-digestion, due to the high solubility of TB in soybean oil (Table II) and enhanced solubilization capacity of micelles. During lipolysis, TB concentration in solution (aqueous and oil phases) rose gradually over a time frame of approximately an hour, as opposed to the rapid increase to approximately 70% of the equilibrium solubility value in the case of dissolution experiments in fed state biorelevant medium in the absence of lipid digestion (Fig. 4). Simulations were run to test the ability of the proposed model to describe drug dissolution in the presence of simulated intestinal fluid and lipid digestion. Parameters used in simulations, determined as described above, are shown in Table III. Comparisons of simulation predictions with experimental dissolution profiles (Figs. 3 and 4) indicate favorable prediction of impact of biorelevant media and lipid digestion on drug dissolution kinetics.

## SEDDS

#### Calculation of Digestion Kinetics Constant

A digestion rate constant ( $k_{dig}$ ) of  $4.7 \pm 0.2 \times 10^{-9}$  mmol/cm<sup>2</sup>s and a digestion inhibition constant ( $k_{inh}$ ) of  $2.8 \pm 0.1 \times 10^{-4}$  1/s were calculated from experimental *in vitro* SEDDS digestion profiles (Fig. 5) using Eq. 2. Favorable model agreement again supports the theoretical description of emulsion digestion as proportional to total droplet surface area.






**Fig. 2** Experimental digestion profile (data points) of soybean oil in the fed state biorelevant medium—measured during the dissolution experiment of TB—agreed well with the proposed digestion kinetics model (continuous line).

### Experimental Drug Release Profile and Calculation of Drug Release Constant from SEDDS

Drug release kinetics studied in the absence of digestive enzyme revealed an initial “burst” release of the drug in the aqueous media upon dispersion of the oil/surfactant/drug mixture. Over 18 h, 14% of drug was released (Fig. 6). First order oil–water interface permeability constant,  $P_{rel}$ , was calculated from experimental release data using Eq. 9 as  $5.55 \pm 1.4 \times 10^{-9}$  cm/s.

TB aqueous solubility (TB solubility in fasted state simulated intestinal fluid) changes once the formulation is dispersed in FaSSIF and Tween 80 molecules get associated with FaSSIF micelles. Therefore, aqueous solubility in the presence of Tween 80 associated micelles was also measured (Table II). Other constant parameters,  $C_{D,water}^{eq}$  and  $C_{D,em}^{eq}$ , which refer to TB solubilities in maleate buffer and in formulation, respectively, were also measured experimentally. Total surfactant concentration,  $C_{surf}$ , together with  $C_{D,water}^{eq}$  and  $C_{D,em}^{eq}$  were used to calculate the molar solubilization constant,  $\chi$ , using Eq. 11 as  $0.2115 \pm 0.008$  mmol/ml.



**Fig. 3** Experimental dissolution profiles and simulations of the model drug TB in maleate buffer and in the fed state biorelevant medium ( $n = 3$  for each dissolving medium).

**Table II** Experimental Solubility Values for the Model Drug TB in Different Media ( $n = 3$ )

Medium	Solubility (mmol/ml)
Maleate buffer-5 mM $\text{Ca}^{2+}$	$4.7 \pm 1.1 \times 10^{-5}$
Maleate buffer-10 mM $\text{Ca}^{2+}$	$7.2 \pm 0.4 \times 10^{-5}$
Fasted state biorelevant medium	$3.4 \pm 0.1 \times 10^{-4}$
Fed state biorelevant medium	$5.2 \pm 0.2 \times 10^{-4}$
Fasted state biorelevant media with Tween 80	$14.3 \pm 0.3 \times 10^{-4}$
Soybean oil	$7.8 \pm 0.1 \times 10^{-1}$


Table II summarizes equilibrium solubility values that were measured in each phase.

### Simulation of Drug Release from SEDDS During Digestion

Kinetic constants calculated separately for each process, formulation digestion and drug release from formulation in the absence of digestive enzyme, were used to solve the developed mathematical model considering both processes occurring simultaneously in order to predict their synergistic effect on released drug concentration from SEDDS over time during digestion. Input parameters to the developed model are given in Table III.

### Comparison of Model Predictions with In Vitro Experimental Results

Multi-component fitting analysis of EPR spectra collected over the course of digestion allowed quantitative determination of the ratio of the spin probe in each phase over time. Model predictions for the amount of drug in the aqueous phase (buffer and micelles),  $C_{D,aq}$ , over time in the presence of digestion of a formulation with 7 mg/ml drug load compared favorably with combined release and digestion experiments analyzed by EPR.



**Fig. 4** Dissolution profiles of the model drug TB in the fed state biorelevant medium and during the digestion of 50 mM of soybean oil ( $n = 3$  for each dissolving medium).

**Table III** Input Parameters to the Developed Models

Input parameters	a) Release from SEDDS	b) Drug dissolution from solid dosage form
Physiological parameters	Value	Value
Bile salt concentration	$5 \times 10^{-3}$ mmol/ml	$12 \times 10^{-3}$ mmol/ml
Phospholipid concentration	$1.25 \times 10^{-3}$ mmol/ml	$4 \times 10^{-3}$ mmol/ml
Critical micelle concentration (21)	$1.6 \times 10^{-3}$ mmol/ml	$1.6 \times 10^{-3}$ mmol/ml
Formulation and drug parameters		
Mean droplet diameter of oil emulsions (10)	403 nm	386 nm
Molecular weight of TB	276.35 mg/mmol	276.35 mg/mmol
Number of digestible FA per mole oil emulsion (15)	2	2
Initial concentration of TB in a) formulation volume, b) solution volume	0.02533 mmol/ml	0.003618 mmol/ml
Initial volume ratio of a) formulation, b) oil in intestinal lumen	1:100	4.8:100
Concentration of Tween 80 associated in BS/PL micelles	8.14 mmol/ml	—
(Molar) solubilization of TB in BS/PL micelles	0.2115 mmol/ml	0.2115 mmol/ml
Solubility of TB in buffer (5 mM $\text{Ca}^{2+}$ /10 mM $\text{Ca}^{2+}$ )	$4.7 \times 10^{-5}$ mmol/ml	$7.2 \times 10^{-5}$ mmol/ml
Solubility of TB in a) fasted, b) fed biorelevant media	$3.4 \times 10^{-4}$ mmol/ml	$5.2 \times 10^{-4}$ mmol/ml
Solubility of TB in a) formulation, b) soybean oil	0.579 mmol/ml	0.788 mmol/ml
Stationary diffusion layer, $h^a$	—	20 $\mu\text{m}$
Particle size of TB <sup>b</sup>	—	20 $\mu\text{m}$
Kinetic parameters		
Diffusion coefficient of TB, $D_D$	—	$8.3743 \times 10^{-10}$ m <sup>2</sup> /s
Diffusion coefficient of micelles, $D_m$	—	$6.5578 \times 10^{-11}$ m <sup>2</sup> /s
Formulation or oil digestion kinetic constant, $k_{dig}$	$4.7 \times 10^{-9}$ mmol/cm <sup>2</sup> s	$3.6 \times 10^{-9}$ mmol/cm <sup>2</sup> s
Formulation or oil digestion inhibition kinetic constant, $k_{inh}$	$2.8 \times 10^{-4}$ l/s	$4.3 \times 10^{-4}$ l/s
a) TB release constant from formulation, b) TB uptake constant into oil, $P_{rel}$	$5.55 \times 10^{-9}$ cm/s	$3.52 \times 10^{-8}$ cm/s

<sup>a</sup> Assumed to be equal to initial particles' radius (25)

<sup>b</sup> Estimated based on particles' separation by controlled sieve mesh; all the other parameters were calculated as explained in the text

## DISCUSSION

In the present study, we investigated the effects of ingested lipids and the lipid digestion process on drug transport in a simulated intestinal lumen considering two different sources of lipids, food-associated lipids and lipid-based drug delivery systems (SEDDS).


The presence of lipids and their digestion products alter greatly the intestinal lumen composition, which consequently influences compounds' solubility, dissolution kinetics and release kinetics in the GI fluids. For both food lipids and lipid-based drug delivery systems, the effects of dynamic lipid digestion on drug transport were investigated. The digestion rate was described using an equation that relates it to the total droplet surface area available to the enzyme and takes into account the lipase inhibition due to the accumulation of FA at the oil/water interface. FA accumulation at the oil/water interface is related to the degree of their solubility in the aqueous phase. FA having short and medium chains were reported to not inhibit or to inhibit less the lipase than long chain FA (15). Similarly, presence of higher concentration of

BS/PL in the aqueous phase may decrease the level of FA accumulation at the interface by increasing the solubilization capacity of the medium. In addition, FA inhibition action described here mainly characterizes the *in vitro* digestion systems, while it is expected to be less relevant *in vivo* where FA are continuously removed by absorption. Based on this equation, digestion rate constants  $k_{dig}$  were calculated as  $3.6 \times 10^{-9}$  mmol/cm<sup>2</sup>s and  $4.7 \times 10^{-9}$  mmol/cm<sup>2</sup>s for food lipids and lipid-based drug delivery systems, respectively. The presence of surfactant Tween 80 at the oil-aqueous interface in lipid based drug delivery systems compared to BS/PL surfactants at the food lipid emulsions surface may contribute to the differences in digestion rates of the two systems, since the interface is considered to be the site of the enzyme-lipid substrate interaction (26). Another difference between the two systems studied is the concentration of BS/PL forming micelles in the fasted and fed biorelevant media. On the other hand, a higher digestion rate of food-associated lipid suspension compared to self-emulsifying systems including the same oil component (Sesame oil: Maisine 35–1, 1:1) was reported previously (12). It should be noted that measured

digestion profiles were based on titration of FA, and it has recently been reported that titration of FA can lead to underestimation of extent of digestion due to only a portion of the FA being ionized (27). Thus, a more rigorous analysis of digestion rate may affect calculated digestion rate constants.


Our investigations regarding the dissolution rates of TB showed that the dissolution enhancement did not follow the same trend as solubility. The dissolution kinetics was faster in the fed state biorelevant medium compared to maleate buffer, following the same trend as in solubility. During food lipid digestion, there was an approximately 4-fold enhancement in solubility, comparing equilibrium solubility in fed state medium to drug dissolved at the conclusion of combined dissolution and digestion experiments. However, during food lipid digestion, the drug dissolution rate from solid dosage form was not enhanced to the same extent as solubility. The initial drug dissolution rates (first 5 min of dissolution experiment) were comparable in the presence and the absence of the digestion process (0.14 mmol/min\*ml *vs.* 0.12 mmol/min\*ml respectively). However, the overall drug dissolution in the presence of digestion was more gradual over a longer period of time than without digestion, despite the observed increased solubility (approximately 4-fold) due to the presence of oil droplets and lipid digestion products. This was in agreement with previous studies showing that the solubility of lipophilic drugs in simulated intestinal fluids increased proportionally to an increased content of surfactants, while the dissolution rates did not increase proportionally (18,28). The lack of a direct proportionality between the enhancement in solubility and the enhancement in dissolution kinetics after food intake was also confirmed by a study (29) that employed real human intestinal fluids obtained under fed conditions. Thus, the present observations support the *in vivo* relevance of including *in vitro* lipolysis models in drug dissolution tests. The lack of significant improvement in dissolution kinetics of TB observed during the lipid digestion process might be related to the relative kinetics of partitioning between the dissolved drug and soybean oil droplets, and associated impact on concentration of drug in the aqueous solution, and thus the driving force for dissolution. Further investigations carried out by means of EPR revealed that indeed the transport of dissolved TB from the fed state bio-relevant medium into soybean oil droplets occurred over a time scale similar to that of drug dissolution (3 hours) (data not shown). These results support the necessity of modifying the classical Noyes-Whitney equation in order to include explicitly: i) the role of colloidal particles in mass transport, and ii) the partitioning process between dissolved drug and oil droplets.

In the absence of digestion, studies of *in vitro* drug release from SEDDS (Fig. 1b) indicated that there is a certain amount of drug in the aqueous phase at time 0. This may be due to a certain amount of the surfactant, Tween 80, associating with micelles upon emulsification of the SEDDS formulation in the



**Fig. 5** Comparison of model simulation results (continuous line) with experimental results (data points) showing rate of digestion in terms of rate of free fatty acid production.


fasted state simulated medium. Due to this association, a certain amount of drug that is initially dissolved in the surfactant component of the formulation may also associate with micelles. This association is, in fact, in agreement with preliminary small-angle neutron scattering (SANS) analysis of the system, where it was shown that there was an alteration in BS/PL micelle composition and possibly size and structure with the addition of formulation into the aqueous system (data not shown). In the absence of digestion, percentage of released drug at 90 min upon introduction of the formulation was 9%, whereas in the presence of formulation digestion this value was 70%. The significantly higher amount of drug released due to digestion can be explained by an active digestion facilitated release mechanism where the drug associated with the digestion products directly partition into the endogenous BS/PL micelles formed in the presence of digestion products. Thus, this active transport mechanism was taken into account while expressing drug release from formulations in the presence of digestion (Eq. 7). Drug solubilization/release into aqueous phase during *in vitro* digestion was previously studied using static (27,30,31) and dynamic lipolysis models (12,32). Fatouros *et al.* (12) studied drug release profiles of the model drug Probutol (logP 8.92), during dynamic *in vitro* lipolysis, formulated with a SNEDDS (Sesame oil: Maisine 35–1:



**Fig. 6** *In vitro* drug release from SEDDS in the absence of digestion.

Cremophor RH 40: Ethanol, 30: 30: 30: 10) and SMEDDS (Sesame oil: Maisine 35–1: Cremophor RH 40: Ethanol, 26.7: 26.7: 26.7: 20) formulations with droplet particle size of  $45.0 \pm 3.4$  nm and  $4.58 \pm 0.84$   $\mu$ m, respectively. Drug release from these formulations ranged between 70% and 95% at 60 min into digestion, which is similar to our findings. The main difference in release profiles between our findings and what has been previously reported is the earlier leveling off of drug release, which is about 0–15 min for Fatouros *et al.*, as opposed to 50 min in our studies. This discrepancy, while likely due in part to differences in formulation composition, might originate in part from differences in analysis of drug concentration techniques. The most conventional way of measuring drug partitioning during digestion so far has involved sampling during *in vitro* digestion, centrifugation of collected samples in order to separate aqueous phase from the formulation phase, and quantification of drug concentration in the aqueous phase (12). While this method has proven to give, in many instances, reliable information about the degree of drug release and partitioning and possible performance of the specific drug delivery system, it may result in misinterpretation of time profiles of this dynamic process since the time spent during centrifugation has been as much as 135 min. In our study, EPR was used as a non-invasive, online method to monitor model drug distribution in different phases. EPR spectroscopy offers advantages of a non-invasive, real time method for analysis of the amount of compound in each phase (water, micelles, and formulation) during *in vitro* digestion, and is thus a powerful tool to monitor drug delivery processes (7,33). Our results on both of the systems studied, food lipids and lipid based drug delivery systems, indicate strong influences of the presence of lipids and lipid digestion on drug transport. During food lipid digestion, the drug dissolution rate from solid dosage form did not increase at the same extent as solubility (approximately 4-fold enhancement), as noted above. Whereas in the case of lipid drug delivery systems, the presence of digestion led to an increase in both the rate and extent of drug release from lipid delivery system emulsion.

Recently, Sugano (34) summarized the effects of fed state intestinal conditions on oral drug absorption via interactions with bile micelles. In particular, the interactions between compounds and bile micelles present in the GI fluids were proposed as the theoretical basis for food effects on co-administered compounds, supporting the central role of micelles in overall oral absorption. Our modeling approach included lipids and dynamic lipid digestion products interacting with endogenous colloidal particles and drug compounds in addition to bile micelles. Furthermore, the model aimed to unify the mechanism behind the observed effects of ingested lipids on two processes—drug dissolution and drug release—based upon fundamental principles of mass transport across oil–water–micelle interfaces as lipolysis



**Fig. 7** Comparison of model simulation results (continuous line) with experimental results (data points) pertaining to drug release from inside of emulsion droplets to the outside aqueous media during formulation digestion.

proceeds. The significance of predicting drug transport between different colloidal phases present during lipid digestion lies in the assumption that simultaneous absorption occurs *in vivo*, and that this absorption process is driven by aqueous drug concentration. Although overall drug absorptive flux has been related to total drug concentration (35), multiple literature reports indicate that drug absorption is driven by the concentration of drug in the aqueous phase (33,35,36).

Several studies (17,23,37) have shown that the classic Noyes-Whitney equation might have to be modified when the dissolution of solid compound takes place in solutions containing solubilizing agents. Previously, we have demonstrated that a model considering micelle-drug partitioning as a pseudo-equilibrium process and an unstirred boundary layer surrounding dissolving particles across which drugs and micelles diffuse could effectively describe drug dissolution in simulated intestinal fluids (18). However, this experimental study and modeling of dissolution of solid compounds did not include the presence of lipid emulsions and the lipid digestion process. In this study, therefore, ingested lipids and the lipolysis process were included in order to more closely mimic the *in vivo* dynamic conditions of the GI fluids after lipid intake. The proposed model presented herein took into account the mass transport of the model drug TB between the aqueous phase—containing micelles—and the oil droplets during oil digestion (19,38).

Close comparison between simulations of drug release/dissolution during digestion and experimental results (Figs. 4 and 7) supports the validity of expressions for kinetic processes for both systems. In addition, several assumptions made solving the model such as increased aqueous solubilization directly related to free FA concentration, and shrinkage of emulsion droplet size proportional to the amount of fatty acid leaving droplets, were supported by the reasonable accuracy of simulation predictions. However, coalescence during digestion of lipid-based systems was reported previously (15).



In cases where oil droplet flocculation and coalescence is prominent during digestion, the model assumption that droplets decrease in size proportional to fatty acid leaving the droplets may not be valid. Lipid digestion was also associated with the formation of several liquid crystalline phases at the water-lipid interface at different stages of the lipolysis (39). Liquid crystalline formation was also correlated with the type of the oil digested (long chain *vs* medium or short chain triglyceride) (40). Our model was tested using a single long chain triglyceride, soybean oil. It should be noted that based on the lipid type, modification on the droplets surface structure (liquid crystal phases) might occur during digestion, in which case model validity might potentially change. Furthermore, we assumed that the enhanced drug solubilization observed during the lipid digestion was directly proportional to the surfactants' concentration. Simple micelle inclusion of FA may be an over-simplification of the more complex colloidal system formation during intestinal lipolysis. However, lacking insight into how colloidal species evolve over time, a first approximation was used to model mathematically the enhancement in solubilization capacity of such colloidal systems due to digestion. Increased solubilization capacity of aqueous phase during digestion in some cases was linked to a supersaturation phenomenon, (41) where an initial supersaturation status is followed by drug precipitation. At the drug load employed in this study, we did not observe a supersaturation as suggested by the lack of precipitate in samples upon centrifugation. Therefore, we did not consider supersaturation and precipitation processes in the presented model. However, higher initial drug loading in SEDDS formulation might potentially induce a supersaturation stage in the aqueous phase upon drug release during digestion. These results substantiate the concept that mechanistic studies based on physiologically relevant *in vitro* experiments can provide a better prediction of drug dissolution and release in the presence of ingested lipids; they can ultimately be combined with permeability studies and pharmacokinetic models, enabling prediction of the overall impact on drug absorption and bioavailability.

## CONCLUSIONS

A physical model considering the simultaneous diffusion of free solute and micelle-solubilized solute across the aqueous boundary layer surrounding a dissolving drug particle, the partitioning and permeation of drug across the oil–water interface of emulsion droplet surfaces, and the lipid digestion process, adequately describes the influence of ingested lipids on both: 1. solid drug dissolution when dosed with food-associated lipids, and 2. drug release from SEDDS in simulated intestinal fluids. It is noted that the proposed model does not address other relevant factors affecting drug absorption—such as

lymphatic drug transport, drug permeability across the intestinal wall, and drug metabolism. Nevertheless, this modeling approach can be utilized in a system-based model that incorporates the aforementioned factors and pharmacokinetics in order to enable quantitative prediction of impact of the presence of fat-rich food or a lipid based drug delivery system in the GI tract on bioavailability of drugs.

## ACKNOWLEDGMENTS AND DISCLOSURES

Fulden Buyukozturk and Selena Di Maio contributed equally to this work. The first and third authors were supported by a National Science Foundation Career Award (grant # CBET-0748048).

## REFERENCES

- Porter CJH, Charman WN. In vitro assessment of oral lipid based formulations. *Adv Drug Deliv Rev.* 2001;50(Supplement 1):S127–47.
- DiSanto AR, Golden G. Effect of food on the pharmacokinetics of clozapine orally disintegrating tablet 12.5 mg: a randomized, open-label, crossover study in healthy male subjects. *Clin Drug Investig.* 2009;29(8):539–49.
- Chow H-HS, Hakim IA, Vining DR, Crowell JA, Ranger-Moore J, Chew WM, *et al.* Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of polyphenon E in healthy individuals. *Anglais.* 2005;11(12):4627–33.
- Berliner LJ. Spin labeling I. Theory and application. New York: Academic; 1976.
- Hubbell W, Altenbach C. Site-directed spin labeling of membrane proteins. In: White S, editor. *Membrane protein structure.* New York: Springer; 1994. p. 224–48.
- Melanson M, Sood A, Torok F, Torok M. Introduction to spin label electron paramagnetic resonance spectroscopy of proteins. *Biochem Mol Biol Educ.* 2013;41(3):156–62.
- Rübe A, Klein S, Mäder K. Monitoring of *in vitro* fat digestion by electron paramagnetic resonance spectroscopy. *Pharm Res.* 2006;23(9):2024–9.
- Jantravid E, Janssen N, Reppas C, Dressman J. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. *Pharm Res.* 2008;25(7):1663–76.
- Sek L, Porter CJH, Kaukonen AM, Charman WN. Evaluation of the *in-vitro* digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products. *J Pharm Pharmacol.* 2002;54(1):29–41.
- Buyukozturk F, Benneyan JC, Carrier RL. Digestion of self-emulsifying drug delivery systems: kinetics and potential impact on lymphatic transport. Manuscript submitted for publication 2013.
- Di Maio S, Carrier RL. Gastrointestinal contents in fasted state and post-lipid ingestion: *in vivo* measurements and *in vitro* models for studying oral drug delivery. *J Control Release.* 2011;151(2):110–22.
- Fatouros DG, Nielsen FS, Douroumis D, Hadjileontiadis LJ, Mullertz A. *In vitro*–*in vivo* correlations of self-emulsifying drug delivery systems combining the dynamic lipolysis model and neuro-fuzzy networks. *Eur J Pharm Biopharm.* 2008;69(3):887–98.
- Sek L, Porter CJH, Charman WN. Characterization and quantification of medium chain and long chain triglycerides and

- their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis. *J Pharm Biomed Anal.* 2001;25(3–4):651–61.
14. Carrière F, Renou C, Lopez V, De Caro J, Ferrato F, Lengsfeld H, *et al.* The specific activities of human digestive lipases measured from the in vivo and in vitro lipolysis of test meals. *Gastroenterology.* 2000;119(4):949–60.
  15. Li Y, McClements DJ. New mathematical model for interpreting pH-Stat digestion profiles: impact of lipid droplet characteristics on in vitro digestibility. *J Agric Food Chem.* 2010;58(13):8085–92.
  16. Reis P, Holmberg K, Watzke H, Leser M, Miller R. Lipases at interfaces: a review. *Adv Colloid Interface Sci.* 2009;147:237–50.
  17. Higuchi WI. Effects of interacting colloids on transport rates. *J Pharm Sci.* 1964;53(5):532–5.
  18. Gamsiz E, Ashtikar M, Crison J, Woltosz W, Bolger M, Carrier R. Predicting the effect of Fed-State intestinal contents on drug dissolution. *Pharm Res.* 2010;27(12):2646–56.
  19. Bikhazi AB, Higuchi WI. Interfacial barrier limited interphase transport of cholesterol in the aqueous polysorbate 80—hexadecane system. *J Pharm Sci.* 1970;59(6):744–8.
  20. Rangel-Yagui C, Pessoa AJ, Tavares LC. Micellar solubilization of drugs. *J Pharm Pharm Sci.* 2005;8(2):147–65.
  21. Spivak W, Morrison C, Devinuto D, Yuey W. Spectrophotometric determination of the critical micellar concentration of bile salts using bilirubin monoglucuronide as a micellar probe. Utility of derivative spectroscopy. (0264–6021 (Print)).
  22. Li J, Carr PW. Accuracy of empirical correlations for estimating diffusion coefficients in aqueous organic mixtures. *Anal Chem.* 1997;69(13):2530–6.
  23. Crison JR, Shah VP, Skelly JP, Amidon GL. Drug dissolution into micellar solutions: development of a convective diffusion model and comparison to the film equilibrium model with application to surfactant-facilitated dissolution of carbamazepine. *J Pharm Sci.* 1996;85(9):1005–11.
  24. Altenbach C. (January 25, 2013); Available from: <https://sites.google.com/site/altenbach/labview-programs/cpr-programs>.
  25. Johnson KC. Intellipharm. In: Intellipharm L, editor. <http://www.intellipharm.com>.
  26. Ransac S, Ivanova M, Panaiotov I, Verger R. Monolayer techniques for studying lipase kinetics. 1998. p. 279–302.
  27. Williams HD, Sassene P, Kleberg K, Bakala-N'Goma J-C, Calderone M, Jannin V, *et al.* Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations. *J Pharm Sci.* 2012;101(9):3360–80.
  28. Horter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. *Adv Drug Deliv Rev.* 1997;25(1):3–14.
  29. Persson E, Gustafsson A-S, Carlsson A, Nilsson R, Knutson L, Forsell P, *et al.* The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. *Pharm Res.* 2005;22(12):2141–51.
  30. Kaukonen AM, Boyd BJ, Charman WN, Porter CJH. Drug solubilization behavior during in vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids. *Pharm Res.* 2004;21(2):254–60.
  31. Fernandez S, Chevrier S, Ritter N, Mahler B, Demarne F, Carrière F, *et al.* In vitro gastrointestinal lipolysis of four formulations of piroxicam and cinnarizine with the self emulsifying excipients Labrasol® and Gelucire® 44/14. *Pharm Res.* 2009;26(8):1901–10.
  32. Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. *J Control Release.* 2008;129:1–10.
  33. Lurie DJ, Mäder K. Monitoring drug delivery processes by EPR and related techniques—principles and applications. *Adv Drug Deliv Rev.* 2005;57(8):1171–90.
  34. Sugano K, Kataoka M, da Costa Mathews C, Yamashita S. Prediction of food effect by bile micelles on oral drug absorption considering free fraction in intestinal fluid. *Eur J Pharm Sci.* 2010;40(2):118–24.
  35. Vertzoni M, Markopoulos C, Symillides M, Goumas C, Imanidis G, Reppas C. Luminal lipid phases after administration of a triglyceride solution of danazol in the Fed State and their contribution to the flux of danazol across Caco-2 cell monolayers. *Mol Pharm.* 2012;9(5):1189–98.
  36. MacGregor KJ, Embleton JK, Lacy JE, Perry EA, Solomon LJ, Seager H, *et al.* Influence of lipolysis on drug absorption from the gastro-intestinal tract. *Adv Drug Deliv Rev.* 1997;25(1):33–46.
  37. Singh P, Desai SJ, Flanagan DR, Simonelli AP, Higuchi WI. Mechanistic study of the influence of micelle solubilization and hydrodynamic factors on the dissolution rate of solid drugs. *J Pharm Sci.* 1968;57(6):959–65.
  38. Surpuriya V, Higuchi WI. Interfacially controlled transport of micelle-solubilized sterols across an oil/water interface in two ionic surfactant systems. *J Pharm Sci.* 1972;61(3):375–9.
  39. Fatouros D, Deen GR, Arleth L, Bergenstahl B, Nielsen F, Pedersen J, *et al.* Structural development of self nano emulsifying drug delivery systems (SNEDDS) during in vitro lipid digestion monitored by small-angle x-ray scattering. *Pharm Res.* 2007;24(10):1844–53.
  40. Kossena GA, Charman WN, Boyd BJ, Porter CJH. Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water-soluble drug. *J Pharm Sci.* 2005;94(3):481–92.
  41. Anby MU, Williams HD, McIntosh M, Benameur H, Edwards GA, Pouton CW, *et al.* Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems. *Mol Pharm.* 2012;9(7):2063–79.